AI-led precision medicine and mechanistic patient stratification for complex chronic diseases

AI-led precision medicine and mechanistic patient stratification for complex chronic diseases

Wednesday, October 9, 2024 3:30 PM to 3:50 PM · 20 min. (Europe/Brussels)
AI in Drug Development and Discovery
Presentation
Theatre 3

Information

Complex chronic diseases present the most difficult and expensive challenges in drug development and healthcare. PrecisionLife has uniquely identified causal biology in over 50 indications to map targets, trials, and treatments to patients based on the molecular mechanisms of their disease and drug response. See how this approach is increasing the probability of success for new diagnostics and treatments and find out about our de-risked precision medicine programs and the rapid progress of our biomarker-led clinical trials.

PrecisionLifeBooth 924PrecisionLife is the clinical-stage precision medicine company for complex chronic diseases. Creating better diagnostic tools and more personalized treatment options for patients with unmet medical needs. Our analytics and AI is unique in its understanding of causal disease biology. Identifying biomarkers to stratify patients by molecular mechanism of either their disease or drug response and link individuals to the drug targets, trials and treatments that will benefit them. With these insights we significantly increase the probability of success throughout the biopharma and healthcare value chain. Accelerating, informing and de-risking drug discovery and clinical development, building highly predictive diagnostics, and in launching more personalized and preventative medicines. To learn more about PrecisionLife, visit precisionlife.com.

Registered attendees

Anna Gaglianese
Anna Gaglianese
Senior Data ScientistAC Immune SA
Ben Fell
Ben Fell
Head Of ResearchAkrivia Health
BNC
Blanaid Ni Chuinneagain
Associate Director, Clinical and Scientific PartnershipsNashBio

Log in